

TECENTRIQ Billing and Coding Guide

Sample billing codes for TECENTRIQ® (atezolizumab)

Effective January 1, 2018, the permanent J-code is **J9022 (injection, atezolizumab, 10 mg)**.

HCPCS			
J9022	Injection, atezolizumab, 10 mg		
ICD-10-CM – Upper Tract Urothelial			
C65.1	Malignant neoplasm of the right renal pelvis	C66.1	Malignant neoplasm of the right ureter
C65.2	Malignant neoplasm of the left renal pelvis	C66.2	Malignant neoplasm of the left ureter
C65.9	Malignant neoplasm of unspecified renal pelvis	C66.9	Malignant neoplasm of unspecified ureter
ICD-10-CM – Lower Tract Urothelial			
C67.0	Malignant neoplasm of trigone of bladder	C67.6	Malignant neoplasm of ureteric orifice
C67.1	Malignant neoplasm of dome of bladder	C67.7	Malignant neoplasm of urachus
C67.2	Malignant neoplasm of lateral wall of bladder	C67.8	Malignant neoplasm of overlapping sites of bladder
C67.3	Malignant neoplasm of anterior wall of bladder	C67.9	Malignant neoplasm of bladder, unspecified
C67.4	Malignant neoplasm of posterior wall of bladder	C68.0	Malignant neoplasm of the urethra
C67.5	Malignant neoplasm of bladder neck		
ICD-10-CM – Non-Small Cell Lung Cancer (NSCLC)			
C34.00-C34.02	Malignant neoplasm of right and left main bronchus, unspecified	C34.30-C34.32	Malignant neoplasm of bronchus and lung; lower lobe
C34.10-C34.12	Malignant neoplasm of bronchus and lung; upper lobe	C34.80-C34.82	Malignant neoplasm of bronchus and lung; overlapping sites
C34.2	Malignant neoplasm of bronchus and lung; middle lobe	C34.90-C34.92	Malignant neoplasm of bronchus and lung; unspecified part

HCPCS=Healthcare Common Procedure Coding System.

ICD-10-CM=International Classification of Diseases, 10th Revision, Clinical Modification.

Additional codes on reverse side.

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

Additional Codes

Additional Codes		
NDC	10-digit 50242-917-01 11-digit 50242-0917-01	1200 mg/20 mL single-dose vial
CPT	96413	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug
	96415	Chemotherapy administration, intravenous infusion technique; each additional hour (List separately in addition to code for primary procedure)

CPT=Current Procedural Terminology.
NDC=National Drug Code.

For more information:



Visit Genentech-Access.com/TECENTRIQ



Call (888) 249-4918 Monday through Friday, 6 a.m.–5 p.m. PT

These codes are not all-inclusive; appropriate codes can vary by patient, setting of care and payer. Correct coding is the responsibility of the provider submitting the claim for the item or service. Please check with the payer to verify codes and special billing requirements. Genentech does not make any representation or guarantee concerning reimbursement or coverage for any service or item.

TECENTRIQ®, its logo and the Access Solutions logo are registered trademarks of Genentech, Inc.



Genentech
A Member of the Roche Group

©2017 Genentech USA, Inc. So. San Francisco, CA
All rights reserved. ACS/110317/0319 11/17 Printed in USA

TECENTRIQ® | **ACCESS SOLUTIONS®**
atezolizumab